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ABSTRACT After a report of reduced seroconversion to measles in infants, aged 6 mo, given vitamin A with their
measles vaccination, serious concerns were raised regarding the safety of the WHO’s recommendation that infants
be supplemented with vitamin A at the time of measles immunization. To determine the impact of coadministered
vitamin A on the antibody response to measles vaccine given to infants aged 9 mo, the more common age for
immunization in developing countries, we conducted a randomized, double-blind, placebo-controlled trial in an
urban slum community in Delhi. Infants (618) were randomly allocated to receive 30 mg vitamin A or a placebo with
the measles immunization. Antibodies to measles were measured by ELISA in serum samples obtained at before
(baseline) and 12 wk after immunization. Overall, the seroconversion rates did not differ between vitamin A
(89.5%) and placebo (87.6%) groups. There were no significant differences in the geometric mean titers in the two
groups (ratio of geometric means, 1.19; 95% confidence interval, 0.97–1.46). Among malnourished infants, the
geometric mean titer was significantly greater in the vitamin A group compared to the placebo group (ratio of
geometric means, 1.57; 95% confidence interval, 1.18–2.0), but seroconversion rates did not differ. There were no
differences in seroconversion rates and geometric mean titers in the two study groups among the well-nourished
children. These results indicate that 30 mg vitamin A does not reduce the immune response to the coadministered
vaccine and, therefore, can be continued to be given safely in public health programs. J. Nutr. 129: 1569–1573,
1999.
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Vitamin A supplementation in children 6 mo–5 y of age
was shown to reduce childhood mortality by 23–30% (Beaton
et al. 1993, Fawzi et al. 1993, Glasziou and Mackerras 1993).
Measles immunization given to infants at 9 mo of age provides
the first realistic opportunity for supplementation. Semba et al.
(1995) reported that 30 mg (100,000 IU) of vitamin A coad-
ministered with a measles immunization at 6 mo of age re-
duced seroconversion compared to a placebo. This effect was
primarily observed in infants who had detectable maternal
antibody at baseline. It was hypothesized that immune en-
hancement by vitamin A may limit the ability of a live-virus
vaccine to establish infection, a view supported by the de-
creased incidence of a vaccine-induced skin rash in the vita-
min A group. These observations by Semba et al. (1995)
caused serious concerns, in many developing countries, regard-
ing the safety of the coadministration of vitamin A and mea-
sles vaccine to infants 9 mo of age, and some critics suggested
abandoning this practice in ongoing programs (Ross 1995). In
most developing countries, coverage under vitamin A prophy-
laxis programs is low after the measles immunization contact,
this contact is therefore an important opportunity for supple-
mentation.
To determine the impact on the antibody response to the
vaccine 12 wk after immunizing infants, at 9 mo of age, with
30 mg of vitamin A coadministered with a standard titer
Edmonston-Zagreb measles vaccine, we conducted an individ-
ually randomized, double-blind, placebo-controlled trial in a
Delhi slum.
METHODS
Study site. The study was conducted in an urban slum of Delhi.
In 1–5-y old children seeking treatment at a health facility in a
neighboring slum, the prevalence of clinical vitamin A deficiency was
;3.5% and that of subclinical deficiency (serum vitamin A levels of
#0.7 mmol/L) was 37% (Bhandari et al. 1997).
In a multi-center study conducted in an adjoining area at the same
time as the present study, vitamin A status of 9-mo-old infants was
assessed by serum retinol and the Modified Relative Dose Response
(MRDR)3 assay (WHO/CHD 1998). The mean serum retinol was
0.89 6 0.36 mmol/L, 29.6% infants had concentrations #0.7 mmol/L,
and 57.5% had inadequate vitamin A stores (MRDR . 0.06).
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Sample size. The a priori hypothesis was that 30 mg of vitamin
A coadministered with a measles vaccine to infants at 9 mo of age
would, 12 wk after immunization, result in a 10% reduction in
seroconversion to measles. Assuming that 92% of controls would
seroconvert after the measles immunization (Job et al. 1991), the
required sample size was calculated to be 238 infants per cell at 95%
confidence level and 90% power (Smith and Morrow 1991). To allow
for the possibility of the observed values for the control group being
different from those assumed, and for 10% attrition, 309 infants per
cell were enrolled.
Enrollment, randomization and study intervention. A house-
hold survey was conducted, and ;700 infants between 6 and 9 mo of
age were identified. If informed parental consent was available, in-
fants were enrolled when they became 9 mo old. Infants were not
included in the study if they had a previous history of measles, contact
with a case of measles or measles immunization, or if they had
received a dose of vitamin A in the previous 4 mo. This information
was ascertained from the caregiver. Infants who had any serious
illness requiring hospitalization or had signs of vitamin A deficiency
(Bitot’s spots, corneal xerosis or keratomalacia) at enrollment were
also excluded.
Infants were randomly assigned to receive vitamin A or a placebo
by using a simple randomization scheme with random permuted
blocks of size eight, i.e., four infants each out of every eight infants
enrolled were randomized to receive vitamin A or a placebo. Vitamin
A and the placebo were packed in individual dose capsules (courtesy
of World Health Organization); the two types of capsules (placebo,
vitamin A) were identical in color, shape and size. The active
ingredient in the vitamin A capsules was 30 mg of retinol palmitate,
whereas the placebo capsules contained soybean oil. Backup doses
were provided for each infant in case the infant spat out the allocated
supplement.
Infants received two capsules during the study period, one at 9 mo
with the measles vaccine and the other at 12 mo of age. Those
assigned to receive the placebo at 9 mo of age were given 30 mg
vitamin A at 12 mo of age. Infants given the vitamin A supplement
at 9 mo of age received the placebo at 12 mo. This scheme ensured
that all infants received 30 mg vitamin A by 12 mo of age without
interfering with the double-blind design of the study.
The study protocol was reviewed and approved by the All India
Institute of Medical Sciences ethics committee.
Immunization and follow up. Subjects were vaccinated with a
single dose, standard titer Edmonston-Zagreb measles vaccine (same
manufacturing lot, obtained from Swiss Serum Institute, Berne, Swit-
zerland), within 20 min of capsule administration, at 9 mo of age, in
the study clinic.
All infants were visited at home by a field worker on post vacci-
nation days 1, 2, 7, 14 and 21 to monitor adverse effects of the
vitamin A and measles vaccine. On these visits, the mother was
queried about any illness symptoms in the infant since the last visit;
the infant was also examined physically, particularly for a measles-like
skin rash.
Laboratory tests. About 3 mL venous blood was obtained from
all infants prior to measles vaccination and 12 wk thereafter. Serum
was separated by centrifugation at 1500 rpm for 10 min within 30–45
min and stored at 220°C.
ELISA was performed to estimate antibody titers by using the
modified method of Voller and Bidwell (1976).
The antigen for ELISA was prepared from the same Edmonston-
Zagreb vaccine strain of measles vaccine that was used for immuni-
zation. Different aliquots were pooled to obtain ;2 L of supernatant,
and the virus was partially purified by ultracentrifugation. ELISA was
standardized by using the International Standard Anti-Measles Se-
rum (66/202) obtained from the National Institute for Biological
Standards and Controls, Blanche Lane, South Mimms, Potters Bar,
Hertfordshire, UK. The pre- and post-vaccination samples from one
study subject were always tested in the same plate; the samples were
coded to ensure that the laboratory staff could not identify pre-
immunization from post-immunization samples. All test serums were
tested in duplicate with and without the antigen-coated wells. The
values of IgG antibodies against measles virus in the test samples was
calculated in reference to the standard curve for the same plate.
Analysis. Seroconversion was defined as a four-fold rise in anti-
body titer over the expected antibody titer caused by the presence of
baseline antibody. This titer at the time of obtaining the post immu-
nization sample was calculated assuming a 6-wk half-life of the
maternally acquired antibody (Markowitz et al. 1990).
Eighteen (11 in the vitamin A and 7 in the placebo group) infants
had evidence of past measles infection at enrollment (pre-immuni-
zation antibody titer .2500) although they had no history suggestive
of measles infection. Because the objective of the study was to
evaluate the impact of vitamin A on the response to primary measles
vaccination (previous history of measles was one of the exclusion
criteria), it was an a priori decision to exclude infants who had a very
high antibody titer at baseline. These 18 infants were therefore
excluded from the analysis.
The analysis was performed using EPI INFO version 6 and SPSS
for Windows software. Categorical variables were compared using the
chi-square test and quantitative outcomes by Student’s t-test. Differ-
ences were considered significant at P , 0.05. A multiple linear
regression analysis restricted to malnourished infants was performed.
In this regression analysis, the outcome variable was the post-immu-
nization measles antibody titer on the logarithmic scale, while vita-
min A or placebo treatment, sex, breast feeding, immunization status
and presence of baseline measles antibody were explanatory variables.
RESULTS
The baseline characteristics did not differ between the two
study groups (Table 1). The pre-immunization blood specimen
was available from all the 618 enrolled infants, but the post-
immunization specimen could not be obtained in 83 of these
infants (vitamin A, 39; placebo, 44).
The response to the measles vaccine was assessed by com-
paring seroconversion rates and geometric mean titers of mea-
sles specific antibody 12 wk after immunization in the vitamin
A and placebo groups; differences in both outcomes were not
significant (Table 2).
We found no significant interaction between vitamin A
administration impact and presence of baseline measles anti-
body, (P . 0.5). On the other hand, a standard test of
interaction (Pocock 1983) suggested a differential impact of
vitamin A on the geometric mean antibody titer in infants
with weight for age Z-score #-2 (P , 0.01). A subgroup
TABLE 1
Baseline characteristics of enrolled infants in the two
intervention groups1
Vitamin A
n 5 309
Placebo
n 5 309
Males 158 (51.1) 163 (52.8)
Height for age Z-score2 21.71 6 1.03 21.58 6 1.01
Infants with HAZ3 ,22 111 (36.0) 102 (33.0)
Weight for height Z-score2 20.73 6 0.93 20.80 6 0.75
Infants with WHZ4 ,22 16 (5.2) 18 (5.8)
Mother literate 178 (57.6) 168 (54.4)
Breast feeding
None 39 (12.6) 37 (12.0)
Partial 268 (87.7) 271 (87.7)
Exclusive 2 (0.6) 1 (0.3)
Immunization status for age
unimmunized 22 (7.1) 14 (4.5)
partially immunized 65 (21.0) 63 (20.4)
fully immunized 222 (71.8) 232 (75.1)
1 Values are n (%) except those marked 2.
2 Values are mean 6 SD.
3 Height for age Z-score.
4 Weight for height Z-score
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analysis was, therefore, performed with infants stratified by
weight for age. The geometric mean antibody titer in the
subgroup of infants with weight for age Z-score # 22 was
significantly greater in the vitamin A group compared to that
in the placebo group, but there were no differences in sero-
conversion rates. Seroconversion rates and geometric mean
titers did not differ between the two study groups among the
well-nourished children (Table 3).
To confirm that the enhanced antibody titer after vitamin
A administration in malnourished infants was not due to
baseline differences, we performed a multiple linear regression
analysis, restricted to malnourished infants, with the logarithm
of post-immunization antibody titer as the dependent variable
(Table 4). Vitamin A treatment was found to significantly
improve the antibody titer in the subgroup of malnourished
infants, after adjustment for potential confounding factors,
including sex, breast feeding, immunization status and pres-
ence of baseline measles antibody (P 5 0.009).
Ten infants (1.6%) developed a measles-like rash within 3
wk of immunization; three of them were in the vitamin A
group. Only two subjects had a bulging fontanelle during the
48-h period after immunization and vitamin A administration,
both of them in vitamin A group. There were no significant
differences in the mean increases in head circumference at 24
or 48 h after vitamin A administration. Other possible adverse
effects, including vomiting, drowsiness or irritability, and tem-
perature $38°C, did not differ between the two intervention
groups (data not shown).
DISCUSSION
The main findings of this study are that vitamin A admin-
istered with the measles vaccine to infants at 9 mo of age had
no adverse effect on seroconversion or geometric mean titer of
measles specific antibody. Our results are consistent with those
of a recently published study from Guinea Bissau (Benn et al.
1997).
In the study by Semba et al. (1995), the adverse impact of
vitamin A on measles vaccine immunogenicity at 6 mo of age
occurred largely in the presence of significant levels of mater-
nally acquired antibody. We did not, however, find an inter-
action of vitamin A impact with the presence of baseline
antibody in the present study. Unlike the findings of the
Indonesian study (Semba et al. 1995), we observed no differ-
ences in the incidence of a measles-like rash after vaccination.
The improved antibody response to measles vaccine in
malnourished infants observed in this study is biologically
plausible. Malnourished infants are more likely to have sub-
TABLE 2
Antibody response to measles vaccine in infants administered vitamin A or placebo 12 wk after
immunization with measles vaccine
Vitamin A
n 5 258
Placebo
n 5 259
Relative risk of
ratio of GM
(95% CI)
Seroconversion rate ($4 fold rise over the
expected titer), n (%) 231 (89.5) 227 (87.6) 1.02 (0.96–1.09)
Baseline geometric mean antibody titer (95% CI) 27.9 (24.4–31.8) 26.1 (23.3–29.2) 1.07 (0.90–1.27)
Geometric mean antibody titer 12 wk post-
immunization (95% CI) 211.8 (182.8–245.5) 178.2 (154.5–205.6) 1.19 (0.97–1.46)
Geometric mean difference between antibody titers
12 wk post-immunization and baseline (95% CI) 116.4 (91.6–147.6) 95.3 (74.8–121.1) 1.22 (0.87–1.71)
TABLE 3
Antibody response to measles vaccine in vitamin A and placebo groups in the subgroup of infants with
weight for age Z-score (WAZ) #22
Vitamin A Placebo
Relative risk or ratio
of GM (95% CI)
Infants with WAZ #22 n 5 128 n 5 124
Seroconverted, n (%) 117 (91.4) 111 (89.5) 1.02 (0.94–1.11)
Baseline geometric mean antibody titer (95% CI) 31.3 (25.2–38.9) 25.5 (22.0–29.4) 1.23 (0.94–1.59)
Geometric mean antibody titer 12 wk post-
immunization (95% CI) 251.2 (202.3–311.9) 160.3 (133.3–192.7) 1.57 (1.18–2.08)
Geometric mean difference between antibody titers
12 wk post-immunization and baseline (95% CI) 138.4 (98.9–193.2) 95.3 (65.8–124.4) 1.53 (0.96–2.42)
Infants with WAZ .22 n 5 130 n 5 135
Seroconverted, n (%) 114 (87.7) 116 (85.9) 1.02 (0.93–1.12)
Baseline geometric mean antibody titer (95% CI) 24.9 (21.4–28.9) 26.7 (22.5–31.7) 0.93 (0.74–1.16)
Geometric mean antibody titer 12 wk post-
immunization (95% CI) 179.5 (147.6–218.3) 196.3 (158.1–243.8) 0.91 (0.68–1.22)
Geometric mean difference between antibody titers
12 wk post-immunization and baseline (95% CI) 98.2 (69.7–138.0) 99.5 (69.3–142.6) 0.98 (0.6–1.62)
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clinical vitamin A deficiency. Several human and animal
studies have reported increased T-cell help, down-regulation
of interferon-gamma (IFN)-g and isotype switching to IgA and
IgG1 after vitamin A supplementation, resulting in an im-
proved humoral response (Friedman et al. 1991, Cantorna et
al. 1995, Semba et al. 1993, Tokuyama and Tokuyama 1996).
Administration of vitamin A with tetanus toxoid in young
children in Bangladesh did not result in an increased antibody
response to the vaccine (Brown et al. 1980). Another study in
Indonesian children reported an improved antibody response
in the vitamin A-treated children compared to those given a
placebo, when Diphtheria-Pertussis-Tetanus (DPT) vaccine
was given 2 wk after supplementation (Semba et al. 1992).
Animal studies have clearly demonstrated that vitamin A
repletion of depleted animals causes significantly improved
antibody response to protein (T cell-dependent) and polysac-
charide (T cell-independent type 2) antigens (Ross 1991).
In the multiple linear regression analysis restricted to mal-
nourished infants, the factors associated with a higher post-
immunization antibody titer were vitamin A administration,
being not previously immunized with DPT or Oral Polio
vaccines, and the presence of baseline measles antibody. There
is a plausible explanation for the paradoxical finding of higher
antibody titer at the end of the study in those who had
baseline antibody. As expected, both seroconversion rate
(75.7% vs. 90.6%, P , 0.001) and geometric mean difference
between the 12-mo and baseline antibody titers (70.3 vs.
112.3, P 5 0.06) were lower in the infants who had baseline
antibody compared to those who had no antibody at baseline.
Therefore, we attribute the higher post-immunization anti-
body titer in these infants to the remaining baseline antibody
after decay in 12 wk, despite a poorer response to the measles
vaccine.
The observed improvement in vaccine immunogenicity in
malnourished infants that were administered vitamin A in this
study should be interpreted with caution; this finding is based
on a subgroup analysis. Because randomization was not per-
formed at the subgroup level, baseline characteristics of the
two intervention groups may have differed. This seems un-
likely in the present situation because, in a multiple linear
regression model restricted to malnourished infants, the im-
pact of vitamin A on post-immunization antibody titer re-
mained significant even after the adjustment for potentially
confounding factors.
Plaque reduction neutralization (PRN), hemagglutination
inhibition and ELISA may all be used for measuring the
antibody response to measles vaccine. The most meaningful
test for the serologic evaluation of immunity status to viral
infections including measles is the neutralization test. Several
earlier studies have compared the results of PRN with those of
ELISA and have shown that ELISA is a sensitive and reliable
assay and could represent an alternative to the PRN (Cremer
et al. 1985, De Souza et al. 1991, Neumann et al. 1985). Also,
the present study was designed to compare the antibody re-
sponse between the two intervention groups and not for eval-
uating the absolute protection against measles. Therefore,
ELISA was chosen as the more convenient and less expensive
assay.
The major implication of these findings is that they set to
rest the controversy about the current recommendation of
combining vitamin A supplementation with measles immuni-
zation of infants at 9 mo of age in public health programs.
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